Development of point-of-care testing devices to improve clozapine prescribing habits and patient outcomes
Shamir N Kalaria,1 Deanna L Kelly21Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD, USA; 2Department of Psychiatry, School of Medicine, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USACorrespondence: Deann...
Guardado en:
Autores principales: | Kalaria SN, Kelly DL |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2e45f311c95b432ea81d205bc7dba4ec |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Reduction in Absolute Neutrophil Counts in Patient on Clozapine Infected with COVID-19
por: Fitri Fareez Ramli, et al.
Publicado: (2021) -
Clinical predictors of response to clozapine in Tunisian patients with treatment resistant schizophrenia
por: Amina Aissa, et al.
Publicado: (2022) -
A survey of personnel and services offered in 32 outpatient US clozapine clinics
por: Robert O. Cotes, et al.
Publicado: (2021) -
Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile
por: de Filippis R, et al.
Publicado: (2021) -
Artesunate prevents rats from the clozapine-induced hepatic steatosis and elevation in plasma triglycerides
por: Li Y, et al.
Publicado: (2017)